Population pharmacokinetics-pharmacodynamics of vedolizumab in patients with ulcerative colitis and Crohn's diseaseMaria Rosario, Irving H. Fox, Nathanael L. Dirks et al.|Alimentary Pharmacology & Therapeutics|2015Cited by 266
DOP058 Pharmacokinetic and pharmacodynamic relationship and immunogenicity of vedolizumab in adults with inflammatory bowel disease: Additional results from the GEMINI 1 and 2 studiesM. Rosario, Irving H. Fox, T. Wyant et al.|Journal of Crohn s and Colitis|2014Cited by 24
P497 Efficacy of continued vedolizumab therapy in patients with Crohn's disease who did not respond to vedolizumab induction therapy at week 6W. Sandborn, Irving H. Fox, Brian G. Feagan et al.|Journal of Crohn s and Colitis|2014Cited by 13
P501 Effects of continued vedolizumab therapy for ulcerative colitis in week 6 induction therapy nonrespondersB G Feagan, Irving H. Fox, Serap Sankoh et al.|Journal of Crohn s and Colitis|2014Cited by 9
Corrigendum to “Efficacy of continued vedolizumab therapy in patients with Crohn's disease who did not respond to vedolizumab induction therapy at week 6” [J Crohns Colitis 8S1 (2014) P497 S274-5]William J. Sandborn, Irving H. Fox, Brian G. Feagan et al.|Journal of Crohn s and Colitis|2014Cited by 7